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Lung adenocarcinoma accounts for ∼40% of lung cancers, the leading cause of cancer-related death worldwide, and
current therapies provide only limited survival benefit. Approximately half of lung adenocarcinomas harbor mu-
tations in TP53 (p53), making these mutants appealing targets for lung cancer therapy. As mutant p53 remains
untargetable, mutant p53-dependent phenotypes represent alternative targeting opportunities, but the prevalence
and therapeutic relevance of such effects (gain of function and dominant-negative activity) in lung adenocarcinoma
are unclear. Through transcriptional and functional analysis of murine KrasG12D-p53null, -p53R172H (conforma-
tional), and -p53R270H (contact) mutant lung tumors, we identified genotype-independent and genotype-dependent
therapeutic sensitivities. Unexpectedly, we found that wild-type p53 exerts a dominant tumor-suppressive effect on
mutant tumors, as all genotypeswere similarly sensitive to its restoration in vivo. These data show that the potential
of p53 targeted therapies is comparable across all p53-deficient genotypes andmay explain the high incidence of p53
loss of heterozygosity in mutant tumors. In contrast, mutant p53 gain of function and their associated vulnerabil-
ities can vary according to mutation type. Notably, we identified a p53R270H-specific sensitivity to simvastatin in
lung tumors, and the transcriptional signature that underlies this sensitivitywas also present in human lung tumors,
indicating that this therapeutic approach may be clinically relevant.
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The p53 transcription factor is frequently counterselected
during tumor development due to its ability to trigger a
multitude of tumor-suppressive effects in response to a
wide variety of cellular stress signals, including DNA
damage and oncogene activation (Freed-Pastor and Prives
2012; Bieging et al. 2014). p53 mutations are present in
∼45% of lung adenocarcinomas and correlate with re-
duced survival (The Cancer Genome Atlas Research Net-
work 2014). Most are missense mutations in the p53
DNA-binding region that can be classified as either con-
tact (interfere directly with DNA binding) or conforma-
tional (induce local or global conformational distortions)
mutations. Both groups affect the DNA-binding ability
of p53 and are thus associated with loss of wild-type func-
tion (Joerger and Fersht 2007).
Mutant p53 is typically highly expressed in tumors,
likely reflecting the presence of p53-inducing stress sig-
nals and the inability of the mutants to transcriptionally
activate the p53-negative regulator Mdm2 (Freed-Pastor
and Prives 2012). Due to their high prevalence and tumor
specificity, p53 mutants are an attractive target for lung
cancer therapy. As mutant p53 remains untargetable,
the identification of mutant p53 tumor dependencies pro-
vides alternative targeting opportunities. Mutant p53
gain-of-function (GOF) phenotypes have been described
in different tissues (Lang et al. 2004; Olive et al. 2004)
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and helped uncover potential targetable vulnerabilities in
p53 mutant breast cancer (Freed-Pastor et al. 2012) and
pancreatic ductal adenocarcinoma (PDAC) (Weissmueller
et al. 2014). However, it remains unclear to what extent
mutant p53 effects may be tissue-specific and even mu-
tant type-specific and, in particular, whether mutant
p53 GOFs are present in lung tumors. p53 targeted thera-
pies, which aim to restore wild-type p53 activity in tu-
mors where the protein is lost, mutated, or inhibited,
represent another appealing strategy for the treatment of
p53-deficient tumors (Cheok et al. 2011; Frezza and Mar-
tins 2012). However, given that p53 mutants can exert
dominant-negative (DN) effects (Freed-Pastor and Prives
2012), the efficacy of wild-type p53 restoration therapies
in mutant tumors is expected to be limited. Despite this,
its potential impact on mutant p53 lung tumors has not
yet been addressed. Interestingly, p53 mutant tumors, in-
cluding lung adenocarcinomas, often display loss of het-
erozygosity (LOH) (Baker et al. 1990; Mitsudomi et al.
2000; Zienolddiny et al. 2001; Liu et al. 2016), suggesting
that wild-type p53 activity may be counterselected even
in the presence of themutant. Hence, the extent of DN ef-
fects of mutant p53 in vivo and, conversely, those of wild-
type p53 in mutant lung tumors remain unclear.
To identify potential therapeutic vulnerabilities in
mutant p53 lung tumors, we characterized the transcrip-
tional and functional phenotypes of murine tumors that
lack p53 or express a contact (R270H, corresponding to
R273H in humans) or conformational (R172H, corre-
sponding to human R175H) p53 mutant. These tumors
were analyzed in the presence or absence of wild-type
p53 functionality (Christophorou et al. 2005) to identify
potential DN and GOF mutant p53 phenotypes, respec-
tively. Our study provides the first comprehensive charac-
terization of wild-type p53, p53-null, and (conformational
and contact) mutant p53 transcriptional signatures and
their functional consequences in vivo. Importantly, these
analyses also expose key therapeutic vulnerabilities of
mutant Kras lung tumors with distinct p53 deficiencies.
Results
Generation of KrasG12D;p53mutant and p53-null lung
tumor models for comparative transcriptional analysis
Lung adenocarcinoma can be recapitulated in mice
through the conditional activation of two genetic altera-
tions frequently coselected in the human disease; namely,
oncogenic activation of KRAS and p53 inactivation (Jack-
son et al. 2005; The Cancer Genome Atlas Research Net-
work 2014). To characterize the effects of p53 mutants in
lung adenocarcinoma, we generated KrasG12D-driven mu-
rine tumors that either lack p53 (p53Fx allele; i.e., p53−) or
carry a contact (p53R270H) or conformational (p53R172H)
mutation (Jonkers et al. 2001; Jackson et al. 2005). In addi-
tion, allmodels contained a secondmodified p53knock-in
allele (p53ER) encoding the switchable p53ER fusion pro-
tein, which enables the functionality of this endogenously
expressed p53 to be controlled through the administra-
tion (p53 “on” state) or withdrawal (p53 “off” state) of 4-
hydroxytamoxifen (4OHT). In the absence of 4OHT,
p53ER is equivalent to a knockout, while 4OHT adminis-
tration restores wild-type function in vitro and in vivo
(Christophorouet al. 2005; Junttila et al. 2010).The follow-
ing tumor models were generated: (1) KrasG12D/+;p53−/ER,
(2) KrasG12D/+;p53R172H/ER, and (3) KrasG12D/+;p53R270H/ER
(Fig. 1A). For simplicity, they are referred to here as
“null,” “R172H,” and “R270H,” respectively. Similar
models with the p53ER allele replaced by p53Fx were also
developed and are mentioned specifically where relevant.
Lung tumorswere inducedasdescribedpreviously (Junt-
tila et al. 2010; Kerr et al. 2016), and multiple lung tumor
cell lines were generated per genotype, each from an
independent tumor never exposed to 4OHT. Using a dif-
ferential attachment method, the presence of tumor-asso-
ciated fibroblasts (TAFs) in tumorcell cultureswas limited
to <8% (Supplemental Fig. S1A). All tumor cell lines
showed full recombination of the relevant alleles, but,
interestingly, none of these was recombined in TAF cul-
tures (Supplemental Fig. S1B; data not shown). Genotypes
were confirmed throughPCRand sequencing (Supplemen-
tal Fig. S1C; data not shown). As expected, both mutants
were expressed at significantly higher levels than the
wild-type protein (p53ER) in mutant cells (Fig. 1B).
To compare the transcriptional signatures of null,
R172H, and R270H lung tumor cells, four independent
cell lines per genotype cultured inMatrigel were analyzed
bymicroarray. Cells were culturedwith andwithoutwild-
type p53 restoration to assess for DN and GOF effects of
the mutants, respectively (Fig. 1A). Differential expres-
sion was defined as a change in gene expression of >1.4-
fold between cohorts. To compensate for intragenotype
variation effects, only genes similarly deregulated across
all cell lines of a given genotype were considered in the
microarray analyses presented (intragenotype variation:
SD < 0.5 across four biological replicates).
‘Canonical’ p53 target genes are efficiently induced
by wild-type p53 in p53 mutant lung tumor cells
To identify potential DN effects of the R172H and R270H
p53 mutants in lung tumors and simultaneously deter-
mine the effect of p53 targeted therapy on these tumors,
we assessed the transcriptional impact ofwild-type p53 on
p53-null and p53 mutant cells. Three-dimensional (3D)
cultures of p53-null, R172H, and R270H (n = 4 per geno-
type) were treatedwith control vehicle or 4OHT, and their
transcriptional profiles were analyzed. Both immediate (2
h after 4OHT treatment) and sustained (8 h after 4OHT)
p53-mediated transcriptional responses were assessed.
Restoration of p53 functionality significantly altered
gene expression in all cell lines. Two hours after p53 resto-
ration, a small number of genes was up-regulated/down-
regulated within each genotype (p53null: 43 genes;
p53R172H: 13 genes; p53R270H 26 genes) (Fig. 1C). Eleven
known p53 targets (Mdm2, Cdkn1a [p21], Bbc3 [Puma],
Ddit4l, Zfp365, Phlda3, Trp53inp, Gtse1, Ccng1, Sesn2,
and Slc19a2) (Utrera et al. 1998; Lo et al. 2001; Bieging
et al. 2014; Quintens et al. 2015) were similarly regulated
across genotypes (Fig. 1D [left], E [top]). Given their early
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induction, these are likely direct p53 targets in lung tumor
cells. In agreement, nine of these genes (82%) were identi-
fied independently as direct p53 targets through ChIP-seq
(chromatin immunoprecipitation [ChIP] combined with
high-throughput sequencing) analysis (Supplemental Ta-
bles S1, S2; Fischer 2017; http://chip-atlas.org), indicat-
ing that the “immediate” p53-responsive genes in lung
tumorcells are likely direct p53 targets in different cellular
contexts. Importantly, since “core” p53 target genes such
as Mdm2 and p21 were efficiently and promptly induced
by p53 restoration in the presence of endogenously ex-
pressed mutant p53, our data argue against a DN effect of
the mutants regarding these “canonical” p53 targets.
Eight hours after treatment, the number of p53-regulat-
ed genes was significantly increased (p53null: 417 genes;
p53R172H: 179 genes; p53R270H: 453 genes) (Fig. 1C). Strik-
ingly, 87 genes (including the common 2-h subset) were
similarly regulated by p53 across all genotypes (Fig. 1D
[right], E). Pathway analysis identified “p53 signaling” as
the top canonical pathway similarly regulated across ge-
notypes (data not shown). Accordingly, most similarly
regulated genes are well-established p53 targets (i.e., “ca-
nonical” targets) (Fig. 1E, blue; Supplemental Table S1,
S2). As seen for the 2-h cohort, the majority of genes sim-
ilarly regulated in all genotypes 8 h after treatment (64%)
is directly bound by p53 in other contexts, suggesting that
these genes are direct p53 targets even if they are not im-
mediate ones. Among these were genes involved in differ-
ent p53-mediated responses, such as cell cycle arrest,
apoptosis, DNA repair, autophagy, and senescence (Sup-
plemental Fig. S1D). Hence, wild-type p53 is able to retain
a significant part of its transcriptional activity in mutant
Figure 1. Transcriptome analysis of the effects
of wild-type p53 on p53-null and mutant lung
tumor cells. (A) Schematic representation of
lung tumor models used in vitro and in vivo
(p53ER models). (B) Expression levels of (mu-
tant) p53, p53ER, and Actb (loading control) in
murine lung tumor cell lines of the indicated
genotypes (immunoblotting). (C–F ) Microarray
analysis of null, R172H, and R270H lung tumor
cell lines. Four independent cell lines per geno-
type were analyzed in the absence (off) or pres-
ence of functional p53 for 2 or 8 h (4OHT
treatment; on). (C ) Venn diagrams showing
the number of genes differentially expressed rel-
ative to vehicle treatment in null, R172H, and
R270H cells 2 h (blue) and 8 h (black) after p53
restoration. (D) Comparative analysis of tran-
scriptional responses between genotypes 2 h
(left panel) or 8 h (right panel) after 4OHT treat-
ment. (E) Heat map showing the expression of
genes similarly altered in null, R172H, and
R270H cells upon 4OHT treatment. (Top panel)
Eleven genes were induced (>1.4-fold) 2 h after
treatment. (Bottom panels) The remaining
genes were similarly altered in all genotypes 8
h after treatment. Known p53 targets are shown
in blue (see Supplemental Table S1). (F ) Heat
maps showing examples of transcriptional DN
effects (left) or “wild-type-like” (right) mutant
p53 transcriptional phenotypes.
Targeting p53 mutant lung tumors
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p53 lung tumor cells, including the induction of some of
its key targets, providing a potential explanation for the
high frequency of p53 LOH in mutant tumors (Baker
et al. 1990; Mitsudomi et al. 2000; Zienolddiny et al.
2001; Liu et al. 2016).
p53 mutants exert DN and wild-type-like transcriptional
effects in lung tumor cells
While p53 restoration had similar effects on the ex-
pression of key p53 target genes across all genotypes,
genotype-specific transcriptional signatures were never-
theless observed, particularly at the 8-h time point (Fig.
1D). Accordingly, 213 out of the 417 genes induced by
wild-type p53 in null cells were not significantly altered
in mutant lines, providing evidence of mutant DN activi-
ty. However, the extent of these DN effects was variable,
spanning from complete failure (R172H: 72 genes, R270H:
27 genes) to reduced ability of wild-type p53 to induce/re-
press its targets in mutant cells (1.2 < fold change < 1.4;
R172H = 143 genes; R270H = 155 genes). Interestingly, a
subset of genes (R172H: 87 genes; R270H: 43 genes)
showed levels of expression in mutant cells (p53 off) sim-
ilar to those seen in null upon p53 restoration, suggesting
that mutant proteins retain wild-type p53 transcriptional
activity (Fig. 1F; data not shown). Analysis of ChIP-seq
data sets suggests that the majority of genes included in
these “wild-type-like” signatures can be directly bound
by p53 (∼70%), while genes included in DN signatures
are less likely to be direct p53 targets (41%–55%) (Supple-
mental Table S2).
Collectively, our microarray analysis revealed that en-
dogenous expression of wild-type p53 in p53 mutant
R172H and R270H lung tumor cells triggers a complex
transcriptional response involving both wild-type tu-
mor-suppressive activity and DN signatures. Interesting-
ly, the majority of the DN phenotypes observed appears
to be partial, as the corresponding p53 target genes are still
regulated by the wild type in mutant cells, albeit to a low-
er degree.
Endogenously expressed wild-type p53 induces cell cycle
arrest and cell death in R172H and R270H mutant lung
tumor cells
To confirm the transcriptional activity of wild-type p53 in
mutant cells, we examined the expression of p53 target
genes in all 12 cell lines by TaqMan analysis. No differ-
ence in the expression of typical “canonical” p53 targets
(e.g.,Mdm2, p21, and Puma) was observed between geno-
types in the absence of treatment (Supplemental Fig. S2A).
p53 restoration resulted in a significant up-regulation of
typical p53 targets in all genotypes 2 and 8 h after treat-
ment (Fig. 2A; Supplemental Fig. S2B), confirming their
responsiveness to wild-type p53 in mutant cells. A high
degree of variationwas observed between cell lines regard-
ing timing and fold of target induction, but, in most cases,
gene induction increased over time (2 h < 8 h time point).
Expression profiling of later time points revealed that p53
targets remained induced up to 72 h after treatment, but
the levels of expression varied significantly between cell
lines both between and within genotypes (Fig. 2B; Supple-
mental Fig. S2C). No clear genotype-specific response pat-
tern could be detected 72 h after p53 restoration, but target
gene expression was frequently higher in the null cells.
DN and wild-type-like expression profiles of mutant cells
were also confirmed byTaqMan analysis (Fig. 2C; data not
shown).
We next asked whether the transcriptional activity of
wild-type p53 in these cells had a functional impact. Res-
toration of p53 significantly reduced the proliferation of
two-dimensional (2D) cultures, and no significant differ-
ences were observed between genotypes (Fig. 3A–C; Sup-
plemental Fig. S3A). The anti-proliferative effects of
4OHTwere p53ER-dependent, as 4OHT treatment had no
effect on the viability of cells lacking the p53ER allele
(KrasG12D/+;p53Fx/Fx cells) (Fig. 3D). No senescence or apo-
ptosis was observed upon p53 restoration on 2D cultures
(Supplemental Fig. S3B,C). In 3D cultures, p53 restora-
tion also induced comparable anti-proliferative responses
in p53-null and mutant cells, but, in these cultures, apo-
ptotic responses were also observed across all genotypes
(Fig. 3E–G).
To establish whether the potent tumor-suppressive
responses observed were due to wild-type activity rather
than mutant p53 depletion (i.e., mutant p53 addiction)
(Alexandrova et al. 2015), we examined the impact of
wild-type p53 on mutant stability. Wild-type p53 restora-
tion decreased mutant p53 protein levels in most cell
lines, indicating that the p53–MDM2 feedback loop was
efficiently restored (Fig. 3H; Supplemental Fig. S3D). Nev-
ertheless, following 4OHT treatment, the majority of
mutant cells expressed higher levels of mutant than
wild-type p53. Hence, p53 restoration induces a robust tu-
mor-suppressive response in both p53-null and mutant
lung tumor cells even when the wild-type protein is ex-
pressed at relatively low levels (i.e., gene regulated
endogenously).
p53 induces comparable tumor suppression in p53-null
and mutant lung tumors in vivo
p53 restoration therapy is an attractive strategy for the
treatment of p53-deficient tumors, which already showed
efficacy in p53-null lung tumor models (Feldser et al.
2010; Junttila et al. 2010). Our in vitro data now suggest
that this therapeutic approach may also be effective in
p53 mutant lung tumors, a more clinically relevant p53-
deficient tumor cohort. To validate these findings in
vivo, independent cohorts of null, R172H, and R270H
lung tumor-bearing mice were treated daily for 6 d with
vehicle or tamoxifen, which restores p53 functionality.
Vehicle-treated (p53 off) animals of all genotypes
showed similar tumor burden, tumor cell proliferation,
and TUNEL positivity as well as comparable tumor grade
distribution (Fig. 4A–E; Supplemental Fig. S4A). As seen
previously in KrasG12D/+;p53ER/ER animals (Junttila et al.
2010), p53 restoration induced cell cycle arrest and apo-
ptosis and decreased the prevalence of high-grade lung tu-
mors in KrasG12D/+;p53Fx/ER mice (Fig. 4B–E, null).
Notably, a similar and significant p53-dependent tumor-
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suppressive response was observed in R172H and R270H
tumors. Indeed, p53-null and p53 mutant tumors exhibit-
ed a comparable decrease in proliferation and increase in
apoptosis following p53 restoration (Fig. 4B–D). Impor-
tantly, all genotypes showed a decrease in the number of
high-grade (but not low-grade) lesions following p53 resto-
ration (Fig. 4E), demonstrating that the tumor-suppressive
effect of p53 restoration on p53-deficient tumors is tumor
grade-specific. In all cases, p53-mediated responses were
more prevalent in tumors expressing elevated levels of
p19ARF (Supplemental Fig. S4B), indicating that p19ARF in-
duction is the main mediator of p53 activation in these
models. Of note, no overall difference in tumor burden
could be observed microscopically, likely due to the high
proportion of low-grade (and thus irresponsive) tumors
present on all genotypes (Fig. 4A; Supplemental Fig. S4A).
Collectively, these data demonstrate that p53 “canoni-
cal” tumor suppression (i.e., cell cycle arrest and apopto-
sis) has a dominant effect over that of mutant p53 in
lung tumors in vivo.
The therapeutic potential of p53 restoration in p53-null
and mutant lung tumor cells is enhanced by combined
exposure to Nutlin-3 or irradiation
The heterogeneity of p53 activation in lung tumors is a
major concern regarding the potential utility of p53 target-
ed therapy regardless of p53 status. Importantly, p53 activ-
ity can be increased by exposure to exogenous p53-
activating agents (e.g., Nutlin-3 and irradiation) (Horn
and Vousden 2007), but whether such “supra-activation”
can be achieved in mutant cells is unclear. The p53-nega-
tive regulator MDM2 is often overexpressed in tumors,
and its inhibition triggers wild-type p53 activation.
MDM2/X inhibitors such as Nutlin-3 can activate wild-
type p53 and have shown promising therapeutic effects
(Vassilev et al. 2004; Cheok et al. 2011). We thus deter-
mined whether Nutlin-3 treatment could enhance the tu-
mor-suppressive potential of wild-type p53 in mutant
lung tumor cells. Encouragingly, null, R172H, and
R270H cells treated with Nutlin-3 and 4OHT showed a
marked decrease in cell viability compared with 4OHT
treatment alone (Supplemental Fig. S5A). These data fur-
ther confirm the therapeutic potential of p53 restora-
tion-based therapy across all p53-deficient genotypes
and highlight the need for adequate p53 activation tomax-
imize its efficacy.
We next tested the impact of p53 restoration in combi-
nation with irradiation, a common lung cancer therapy.
Combined exposure to wild-type p53 and irradiation sig-
nificantly reduced viability in cell lines fromall genotypes
(Supplemental Fig. S5B), demonstrating that the activa-
tion of wild-type p53 by DNA damage is not impaired
by the presence of mutant p53. These results were
Figure 2. Regulation of expression of known
p53 targets by wild-type p53 in p53-null and
mutant lung tumor cells. Representative Taq-
Man data of two independent runs showing
expression of p53 targets in null, R172H,
and R270H cell lines. (A) Expression of the in-
dicated genes 2 and 8 h after p53 restoration
(p53 on) relative to the vehicle-treated (p53
off) null cell line (first bar). Four cell lines
per genotype are shown (see Supplemental
Fig. S2B). (B) p53 target gene expression 24,
48, and 72 h after p53 restoration relative to
vehicle at the corresponding time points.
One cell line per genotype is shown (see Sup-
plemental Fig. S2C). (C ) Expression profiling
of genes differentially expressed between
p53-null and the indicated mutant cells.
Two cell lines per genotype are shown. Values
are shown relative to the average of the corre-
sponding null samples. (A–C ) The SD of the
triplicate mean per cell line is shown.
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subsequently validated in lung tumors in vivo. Radiation
alone had no significant impact on tumor cell prolifera-
tion or apoptosis and did not increase the apoptotic effect
of p53 restoration therapy at the time point analyzed (24 h)
(data not shown). Of note, short-term (24 h) (Fig. 4F) and
long-term (6 d) (Fig. 4B) p53 restoration had similar anti-
Figure 3. Wild-type p53 induces similar cell cycle arrest and apoptotic responses in p53-null, R172H, and R270H lung tumor cells. (A)
Growth curves of null (left), R172H (middle), and R270H (right) cells following vehicle (p53 off) or 4OHT (p53 on) treatment. One repre-
sentative cell line per genotype is shown (see Supplemental Fig. S3A). n = 4. Circles depict technical triplicates, and the average ± SD is
indicated. (B) Viability of cells of the indicated genotypes 72 h after p53 restoration, relative to vehicle. Four independent cell lines per
genotype are shown ±SEM. (C ) Representative (n = 4 per genotype) BrdU/PI analysis (FACS) of the indicated cells 24 h after vehicle or
4OHT treatment. The percentage of cells in S phase is indicated. (D) Viability ofKrasG12D;p53Fx/Fxmurine lung tumor cell lines 72 h after
4OHT/Ctrl treatment. One representative cell line is shown. n = 3. Circles represent technical replicates, and themean ± SD is shown. (E)
The percentage of BrdU-positive cells (FACS) in null, R172H, and R270H cultures 72 h after 4OHT treatment, relative to vehicle. Symbols
denote independent cell lines. SEM of the average percentage per genotype is indicated. (F ) Representative data (n = 3) showing the per-
centage of dead cells for one cell line per genotype 72 h after vehicle/4OHT treatment. (G) Representative images of cleaved caspase 3
staining of null, R172H, and R270H cells 72 h after vehicle/4OHT treatment. Arrowheads indicate examples of positive staining. Bar,
100 µm. (H) Expression levels of (mutant) p53, p53ER, andActb 24 h after vehicle (“−“) or 4OHT (“+”) treatment, based on immunoblotting
(see Supplemental Fig. S3D). (B,E) One-way ANOVA. (D,F ) t-test. (ns) Nonsignificant; (∗) P < 0.05. Data presented were generated from 2D
(A–D,H) or 3D (E–G) cultures of the indicated lung tumor cells.
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proliferative and anti-apoptotic (data not shown) effects,
indicating that the tumor-suppressive impact of wild-
type p53 is sustained over time across all genotypes. Im-
portantly, combined p53 restoration and irradiation treat-
ment resulted in an enhanced cytostatic effect relative to
p53 restoration (Fig. 4F), demonstrating that the in vivo
impact of p53 targeted therapy can be improved through
exogenous activating signals. However, the enhanced effi-
cacy of this combined treatment was less marked in
R270H tumors than in p53-null and R172H lesions, sug-
gesting that p53-deficient lung tumors may exhibit geno-
type-specific therapeutic vulnerabilities.
R172H and R270H p53 mutants exhibit transcriptional
GOFs in lung tumor cells
Our data show that p53mutations are unlikely to be ama-
jor obstacle for the efficacy of p53 restoration-based lung
cancer therapy. Nevertheless, our transcriptional analy-
ses uncovered p53 mutation type-specific signatures in
lung tumor cells (Fig. 1C,D), suggesting that these mu-
tants may exhibit distinct susceptibilities in other con-
texts. Since p53 genotype-specific signatures may have
therapeutic implications, we carried out an unbiased com-
parative analysis of all p53 genotypes under normal condi-
tions (p53 off) to identify putative mutant GOFs.
Multiple genes (n = 465) were differentially expressed in
mutant (R172H +R270H) lung tumor cells relative to null,
indicative of mutation type-independent mutant p53 (i.e.,
“universal”) transcriptional GOFs. Genes involved in cell
death and survival, cellular movement, and cell cycle
topped the list ofmolecular functions significantly altered
(Fig. 5A), suggesting that p53 mutations may affect the
proliferative and invasive capacity of lung cancer cells,
as described in other tumor types (Freed-Pastor et al.
2012; Weissmueller et al. 2014). However, no significant
differences in colony size, number, or invasiveness (Fig.
5B–E; Supplemental Fig. S6A–C) or tumor cell metastatic
potential in vivo (Fig. 5F; Supplemental Fig. S6B,C) could
be detected between null, R172H, and R270H cells using
both p53ER- and p53Fx-derived models. These data show
that the GOF transcriptional signatures of p53 mutant
cells do not necessarily result in measurable GOF cellular
phenotypes and that p53-null, p53 contact, and p53 con-
formational mutant lung tumor cells have comparable
proliferative capacity and invasive potential.
Figure 4. p53 restoration has a comparable thera-
peutic impact on p53-null andmutant lung tumors
in vivo. (A) Representative hematoxylin and eosin-
stained sections showing lung tumor burden. (B)
Quantification of Ki67+ cells per tumor (immuno-
histochemistry) in null, R172H, and R270H mice
after 6 d of treatment (vehicle: “p53 off”; tamoxi-
fen: “p53 on”). (C ) Illustrative data showing
TUNEL staining (arrowheads) in lung tumor sec-
tions. Bar, 60 µm. (D) Quantification of TUNEL-
positive cells per tumor 24 h after treatment. (B,
D) Circles represent independent tumors, and av-
erage value per cohort ±SEM is shown (t-test).
Three or more mice per cohort were analyzed. (E)
Quantification of low- and high-grade tumor fre-
quencies in null, R172H, and R270H mice treated
for 6 d. A minimum of 68 tumors per cohort (from
five or more mice) was analyzed. (F ) Quantifica-
tion of Ki67-positive cells per tumor (immunohis-
tochemistry) in null, R172H, and R270H tumors
24 h after treatment with tamoxifen (p53 on) or ta-
moxifen and irradiation (p53 on + IR). Independent
tumor values and average positivity per cohort ±
SEM are shown. A minimum of three mice per co-
hort was used. (B,D,F ) t-test. (E) Fischer’s exact
test. (ns) Nonsignificant; (∗) P < 0.05; (∗∗) P < 0.01;
(∗∗∗) P < 0.001.
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Figure 5. R172H and R270Hmutants exhibit both common andmutant type-specific transcriptional GOFs. (A, left) Heat map depicting
genes differentially expressed between p53-null and p53mutant (R172H+R270H) cell lines, based onmicroarray analysis. (Right) Molec-
ular functions most significantly altered between the genotypes shown (Ingenuity Pathway Analysis [IPA]). (B) Average colony sizes of
independent p53 mutant and p53-null cell lines (symbols) grown in triplicate in 3D for 72 h, relative to internal control, are shown ±
SEM. (C ) The number of colonies per field of view formed by p53 mutant and p53-null cell lines (symbols) grown in 3D ±SEM. (D) Migra-
tion potential of the indicated genotypes (scratch assay). Mean velocity per genotype ±SEM is shown. Independent tumor cell lines from
both p53Fx-derived (squares) and p53ER-derived (circles) models are shown. (E) Representative data (n = 2 per genotype) show the percent-
age of p53-null and p53mutant colonies that invaded >120 µm throughMatrigel. Replicates for one cell line per genotype ±SD are shown.
(F ) Survival (top) and tumor frequency (bottom) of recipient mice transplanted (intravenously) with cell lines of the indicated genotype.
Log-rank (Mantel-Cox) test. (G) Heat map depicting genes differentially expressed between R172H and R270H lung tumor cells. (H) The
top canonical pathways significantly altered between R172H and R270H cells (IPA). (I ) The expression of mevalonate (MVA) pathway
genes in null, R172H, and R270H cells is displayed (heat map). Null cells are shown in the absence (“null”) and presence (“wild-type”)
of 4OHT treatment (8 h). (J) Schematic representation of the MVA pathway, with genes significantly deregulated between R172H and
R270H cells highlighted in red. t-test, P < 0.05. (K ) The expression of the indicated genes in null, R172H, and R270H cells (3D) was ana-
lyzed by TaqMan and normalized to Gapdh. Representative data (n = 3 runs) show one cell line per genotype ±SD of triplicates. (L) Intra-
cellular cholesterol levels of R172H and R270H cells relative to average R172H values and normalized to protein levels. Representative
data show two cell lines per genotype (represented by different symbols) n = 4 analyzed per genotype, and ±SDof triplicates is indicated. (B–
E,K ) One-way ANOVA. (L) t-test. (ns) Nonsignificant; (∗∗∗) P < 0.001.
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Unexpectedly, our comparative analysis revealed signif-
icant transcriptional distinctions between R172H and
R270Hcells,with 972genesbeingdifferentially expressed.
Lipidmetabolism—and themevalonate (MVA)pathway in
particular—was themost differentially regulated pathway
(Fig. 5G–I). The MVA pathway regulates multiple cellular
processes through the production of a wide range of mole-
cules, such as cholesterol and farnesylation and geranyl-
geranylation intermediates (Mullen et al. 2016). Up-
regulation of MVA pathway genes was associated previ-
ously with mutant p53 activity in breast cancer cells
(Freed-Pastor et al. 2012). Our data indicate that this
GOFmaynotbeuniversal but rathermutation type-specif-
ic. Indeed, themajority ofMVApathway geneswas up-reg-
ulated inR270Hmutant cells relative toR172H (Fig. 5I–K).
R270HMVA pathway gene expression was also enhanced
relative to p53-null and “wild-type” cells (null + 4OHT)
(Fig. 5I). Wild-type p53 restoration did not restore normal
MVA pathway gene expression in R270H cells (Supple-
mental Fig. S6D, null p53 on vs. R270H), demonstrating
the dominance of this R270Hmutant phenotype.
p53 R270H lung tumor cells exhibit increased
dependency on MVA pathway gene expression
relative to R172H cells
Given that cholesterol is a major product of the MVA
pathway (Mullen et al. 2016), we assessed cholesterol lev-
els in our cultures and found a significant increase in
R270H tumor cells (Fig. 5L), which functionally validated
the transcriptional GOF observed. Under physiological
conditions, theMVApathway is activated by low intracel-
lular sterol concentrations or increased demand for cho-
lesterol (Mullen et al. 2016). Our data suggest that this
“feedback loop” may be deregulated in R270H cells, but
the relevance of this transcriptional phenotype was
unclear.
We therefore asked whether R270H cells had an in-
creased dependency onMVA pathway function compared
with other p53-deficient cells. The MVA pathway can be
efficiently down-regulated by statins (Fig. 5J), a group of
drugs widely used in the clinic to lower de novo cholester-
ol biosynthesis and serum low-density lipoprotein choles-
terol levels through the specific inhibition of HMG-CoA
reductase (HMGCR) (Istvan and Deisenhofer 2001; Cho-
lesterol Treatment Trialists Collaboration 2010). To com-
pare their sensitivity to MVA pathway inhibition, p53-
null, R172H, and R270H 3D lung cell cultures (combining
p53Fx and p53ERmodels) were treated with statin (simvas-
tatin [Stn]) or vehicle for 72 h. Statin treatment resulted in
decreased colony growth across all genotypes. Neverthe-
less, this effect was more significant in R270H cells (Fig.
6A). The enhanced sensitivity of R270H cells to statin
was not due to preferential degradation of thismutant pro-
tein by the treatment (Fig. 6B), as described previously for
conformational p53 mutants in a different context (Par-
rales et al. 2016).
The reduced growth of lung tumor cultures following
statin treatment was fully rescued by MVA administra-
tion, demonstrating that the effects of statin treatment
were due toMVApathway inhibition (Fig. 6C).MVA path-
way gene expression is regulated by the transcription fac-
tor Srebf2 (also known as Srebp2), which was also up-
regulated in R270H cells (Fig. 5I,K). To determinewhether
Srebf2 activity was essential to the MVA pathway pheno-
type of R270H cells, its cleavage and subsequent activa-
tion were inhibited by the administration of the Srebf
inhibitor fatostatin (Kamisuki et al. 2009). Fatostatin
treatment inhibited the expression of MVA pathway
genes in all genotypes (Fig. 6D). However, similarly to sta-
tin, fatostatin treatment was significantly more deleteri-
ous to R270H cultures than to R172H or null (Fig. 6E).
Since upon fatostatin treatment all genotypes expressed
comparable levels of MVA pathway genes, these data
demonstrate that R270H lung tumor cells are signifi-
cantly more dependent on this pathway than other p53-
deficient genotypes. Srebf2 knockdown recapitulated the
effects of fatostatin onR270H cells, confirming the depen-
dence of these cells on Srebf2 for MVA pathway gene ex-
pression and colony growth (Fig. 6F,G; Supplemental
Fig. S6E). These data suggest that abnormal regulation of
Srebf2 is an important transcriptional GOF of p53R270H
in lung tumor cells.
Statin treatment induces a robust therapeutic response
in spontaneous p53R270H mutant (but not p53R172H)
KrasG12D-driven lung tumors
To test the relevance of this p53 R270H-specific GOF in
vivo, we generated lung tumors in KrasG12D/+;p53Fx/Fx,
KrasG12D/+;p53R172H/Fx, and KrasG12D/+;p53R270H/Fx mice.
For consistency, these tumors are again referred to here as
null, R172H, R270H, respectively (Fig. 7A–D). Similarly
to in vitro data, R270H lung tumors expressed signifi-
cantly higher levels of the MVA pathway genes Mvd and
Sqle than normal lung and R172H lesions (Fig. 7A). To
test the sensitivity of these tumors toMVA pathway inhi-
bition, lung tumor-bearingmicewere treatedwith vehicle
(Ctrl) or Stn (statin) for 6 d. In vivo, statin treatment had no
significant anti-proliferative or apoptotic effect on p53-
null and R172H lung tumors (Fig. 7B,C). In contrast,
R270H tumors showed a striking response to statin treat-
ment, which impacted both tumor cell proliferation
(R270H mean values: 13% Ctrl; 7% Stn) and survival
(<0.1% vs. >1% average TUNEL
+
cells in vehicle [Ctrl]
vs. Stn-treated samples, respectively). Notably, the dra-
matic cytotoxic effect of statin treatment on p53 R270H
lung tumors was characterized by an increase in both
the number of TUNEL-positive tumors and TUNEL posi-
tivity per tumor (Fig. 7C,D; data not shown). No effect of
statin on tumor grade distribution was observed, suggest-
ing that this treatment is similarly effective in low- and
high-grade lung tumors (Supplemental Fig. S6F).
Continuous, long-term statin treatment of an R270H
orthotopic lung tumormodel significantly reduced tumor
burden and improved host survival, demonstrating the
therapeutic potential of this statin on lung tumors harbor-
ing this particular p53 mutation (Fig. 7E,F). Finally, we
asked whether the p53 mutation specificity of MVA path-
way deregulationwas also observed in human tumors. For
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that purpose, RNA sequencing (RNA-seq) data from The
Cancer Genome Atlas (TCGA) lung adenocarcinomas
with R175, R273, or other known conformational and
contact p53mutations (Supplemental Table S3) were ana-
lyzed. As shown in Figure 7G, the expression of MVA
pathway genes was significantly enhanced in R273 rela-
tive to R175 mutant tumors but also in other lesions
with p53 contact mutations relative to conformational
mutant tumors. Hence, human lung cancer exhibits a
p53 mutation type-specific GOF similar to that seen in
murine tumors and thus, potentially, a comparable thera-
peutic sensitivity.
Our comprehensive profiling of DN and GOF effects of
distinct p53mutants enabled the identification of mutant
p53 lung tumor vulnerabilities that can be potentially ex-
ploited therapeutically. Importantly, our study also dem-
onstrated that some of these liabilities are likely to be
mutation type-dependent.
Discussion
Lung cancer is the leading cause of cancer-related death
worldwide, reflecting its high incidence and the limited
efficacy of available therapies. The identification of ther-
apeutic vulnerabilities in p53 mutant lung tumors pro-
vides important targeting opportunities for a significant
proportion of lung adenocarcinomas. Given the accumu-
lation of p53 mutants in tumors, their oncogenic impact
can go beyond loss of wild-type function. Indeed, mutant
p53 DN and GOF phenotypes have been described
(Freed-Pastor and Prives 2012; Bieging et al. 2014), but
whether these are universal phenotypes or tumor and/
or mutation-specific traits remained unclear. Our study
provides the first evidence of DN and GOF effects of
distinct p53 mutants in lung tumors and identifies ther-
apeutic vulnerabilities associated with distinct p53 alter-
ations. We show that p53 binding and conformational
Figure 6. Enhanced sensitivity of p53 R270H lung tumor 3D cultures to MVA pathway inhibition. (A) Representative data (n = 2 runs)
show the percentage of viable cells following 72 h of statin (Stn) treatment, relative to vehicle. Symbols represent independent tumor
cell lines from both p53Fx-derived (squares) and p53ER-derived (circles) models. SEM per genotype is shown. (B) Expression of mutant
p53 and Actb (immunoblotting) in three R172H and R270H cell lines 24 h after Stn (+) or vehicle (−) treatment. (C ) Viability of cells fol-
lowing 72 h of Stn or Stn +MVA treatment, relative to vehicle (Ctrl). Representative data for one cell line per genotype are shown. n = 3
tested; ±SD of triplicates. (D) Expression of the indicated genes (TaqMan) in p53-null, R172H, and R270H cells in the presence (Srebf in-
hibitor) or absence (Ctrl) of the Srebf inhibitor fatostatin (72 h). (E) Cell viability 72 h after treatment of the indicated cellswith fatostatin or
Ctrl. (D,E) Representative data (of n = 3 runs) show one cell line per genotype ±SD of triplicates. (F ) Expression of the indicated genes (Taq-
Man) in R270Hcells following shRNAknockdown of Srebf2with four different constructs (#1–#4) or all four constructs (pool). (G) Average
colony size per field of view of R270Hcells following Srebf2 knockdown. (F,G) Representative expression data (of n = 2 runs) shows one cell
line per genotype ±SD of triplicates, relative to nontargeting control (NTC). (A) One-wayANOVA. (C,F,G) t-test. (D,E) Two-way ANOVA.
(ns) Nonsignificant; (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001. All data were obtained from 3D cultures of the indicated genotypes.
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mutants exhibit both common and distinct therapeutic
vulnerabilities relative to p53-null tumors and even be-
tween each other.
Our data argue against a major DN effect of mutant p53
in lung tumor cells. Indeed, while we found evidence of
transcriptional DN activity for both mutants, multiple
key p53 targets were efficiently regulated by wild-type
p53 inmutant cells. It has been proposed that p53mutants
interfere with wild-type function through direct binding
to the wild-type protein, with the resulting heterote-
tramers being transcriptionally impaired (Milner and
Medcalf 1991; Chan et al. 2004). Interestingly, analysis
of ChIP data sets (http://chip-atlas.org; Fischer 2017) re-
vealed that the large majority (64%–82%) of genes simi-
larly regulated by wild-type p53 across all genotypes is
direct p53 targets. Since these targets were induced in
cells expressing higher levels of mutant than wild-type
protein, these data suggest that p53mutant:wild-type het-
erotetramers are likely to retain some wild-type activity
in lung tumor cells. Alternatively, these transcriptional
profilesmay be explained by a bias of thewild-type protein
toward homotetramer formation in these cells. In con-
trast, ChIP data analysis revealed that only 41%–55% of
genes associated with DN mutant signatures are direct
p53 targets, suggesting that mutant p53 may exert some
of these effects by interfering with the activity of tran-
scription factors induced by wild-type p53.
Importantly, the transcriptional activity retained by
wild-type p53 in mutant p53 lung tumors was sufficient
to induce anti-proliferative and apoptotic responses sim-
ilar to those observed in p53-null samples, potentially
explaining the selective pressure for the loss of the
wild-type allele in mutant p53 lung tumors in humans.
This dominant effect of the wild-type p53 protein has
important therapeutic implications. Indeed, since the
DN activity of mutant p53 was unable to prevent wild-
type p53 tumor suppression in lung tumors in vivo,
our data show that wild-type p53 restoration and activa-
tion strategies should be equally effective on p53-null
and mutant tumors independently of the p53 mutation
present.
It is possible that the dominant effect of wild-type p53
in p53 mutant cells is lung tumor-specific, as wild-type
p53 restoration was shown previously to induce a more
potent effect in p53-null lymphomas and angiosarcomas
than in mutant lesions (Wang et al. 2011). However, in
Figure 7. Increased MVA gene expression and sensi-
tivity to statin treatment in p53 contact mutant lung
tumors. (A) Expression of Pmvk,Mvd, and Sqle (Taq-
Man) in null, R172H, and R270H lung tumors (Fx
model) normalized to 18S expression. Expression is
shown relative to the average of null tumors ±SEM
per genotype. n = 10 normal lungs; n = 15 tumors per
genotype; n≥ 4 mice per cohort. (B) The percentage
of Ki67-positive cells per tumor in vehicle-treated
(Ctrl) or Stn-treated (6 d of treatment) null, R172H,
and R270H mice. A minimum of 47 tumors was ana-
lyzed. n = 5 mice per cohort. The average positivity
per cohort ±SEM is shown. (C ) The percentage of
TUNEL-positive cells per tumor in Ctrl or Stn-treated
mice (6 d of treatment). Aminimumof 93 tumors (n =
5 mice) was analyzed per cohort. (A–C ) Symbols
depict independent normal tissues per tumor sam-
ples. (D) Representative TUNEL staining (arrow-
heads) in lung tumor sections from Ctrl or Stn-
treatedmice. Bar, 50 µm. Lung tumor burden (lucifer-
ase activity; E) and survival (F ) of recipient mice
transplanted (intravenously) with R270H lung tumor
cells and treated with vehicle or Stn. n≥ 5 mice per
cohort. Daily treatmentswere started (week 0) 14 d af-
ter transplantation. Log-rank (Mantel-Cox) test. (G)
Heat maps depicting expression of MVA pathway
genes significantly up-regulated in human p53 con-
tact mutant lung adenocarcinomas relative to confor-
mational mutant tumors. Samples with a R175 or
R273 mutation are shown independently (left) or
combinedwith other known conformational and con-
tact mutations (right) (see Supplemental Table S3).
An asterisk denotes a tumor with a R175H and a
C277F (contact) mutation. (A–C,E) t-test. (∗) P <
0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001.
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that study, p53 restoration involved the use of a hypomor-
phicwild-type p53, potentially explaining the discrepancy
with our findings.
Murine studies suggest that p53 targeted therapymaybe
of benefit only to patients with advanced lung tumors, as
p53 is adequately activated only in those lesions (Feldser
et al. 2010; Junttila et al. 2010). Nevertheless, this ap-
proach has the potential to benefit a large patient popula-
tion, as most lung tumors are diagnosed at advanced
stages. Furthermore, we observed similar anti-prolifera-
tive andapoptotic responses after24hand6dof treatment,
suggesting that p53 restoration can provide long-term pro-
tection against high-grade tumor cells. Importantly, we
show that the in vivo efficacy of this therapy can be im-
proved through exogenous p53 activation (e.g., irradia-
tion). Since lung cancer therapy relies strongly on DNA
damage-inducing agents (Reck et al. 2013), the therapeutic
impact of p53 restoration is likely to be enhanced by stan-
dard therapy. Conversely, our data imply that functional
nonactive wild-type p53 may be retained in mutant p53
low-grade tumors, where its activity can be potentially en-
gaged therapeutically.
Surprisingly, we were unable to identify a common
(R172H +R270H) functional GOF in lung tumor cells or
evidence of enhanced invasiveness/metastatic potential
of p53 mutant cells relative to p53-null. While this is con-
sistent with the comparable lung tumor development ki-
netics reported for p53-null and mutant mice (Jackson
et al. 2005), it is in striking contrast to data from PDAC
(Weissmueller et al. 2014) and breast cancer (Freed-Pastor
et al. 2012) models. Interestingly, mutant p53 lung tumor
cells showed discrepancies with these models at both
transcriptional (unlike in PDAC, Pdgfrb was not overex-
pressed inmutant lung tumor cells) and functional (unlike
in breast models, MVA pathway gene up-regulation did
not increase lung tumor cell invasiveness) levels. These
data demonstrate that mutant p53 GOF phenotypes are
tissue-specific and imply that the vulnerabilities of mu-
tant p53 tumors are likely to be tissue/context-dependent.
Unexpectedly, we found that p53 conformational and
contact mutant murine and human lung tumors exhibit
distinct transcriptional signatures. In particular, R270H
mutant tumors displayed enhanced MVA pathway gene
expression, and R270H murine cell lines showed a high
dependence on this transcriptional signature. Indeed,
MVA pathway inhibition through simvastatin treatment
induced robust cell cycle arrest and apoptotic responses
in R270H lung tumors but had no significant impact on
p53-null or R172H lung tumors.
It is unclear how p53 mutants exert mutation-specific
transcriptional phenotypes, but these effects likely in-
volve differential mutant binding towild-type p53 (DN ef-
fects) or other transcriptional factors (DN and GOF
effects) (Freed-Pastor and Prives 2012). Alternatively, the
mutants may bind the same factors but exhibit differen-
tial cooperativity and thus distinct promoter affinities
(Schlereth et al. 2013).
This study shows that the analysis of lung tumor sub-
set-specific transcriptional signatures can lead to the iden-
tification of tumor vulnerabilities to agents already
available in the clinic, as shown here for simvastatin. Im-
portantly, TCGA data suggest that the R270H-dependent
MVA pathway GOFmay be shared by other DNA contact
mutants in human lung tumors. Notably, while the ef-
fects of statins on cancer remain controversial (Mullen
et al. 2016), there are reports of improved survival among
statin-treated lung cancer patients (Cardwell et al. 2015;
Lin et al. 2016). Based on our findings, it would be impor-
tant to determinewhethermutant p53 status is associated
with that benefit. Moreover, as seen in our models, MVA
gene expression profiling may help identify lung cancer
patients that could profit from statin repurposing for can-
cer therapy.
Materials and methods
Mice, adenoviral infection, and treatments
This research was regulated under the Animals (Scientific
Procedures) Act 1986 Amendment Regulations 2012 following
ethical review by the University of Cambridge Animal Welfare
and Ethical Review Body (AWERB). For the generation of endoge-
nous lung tumor models, mixed background (C57Bl/6/129/Sv)
KrasLSL-G12D/+;p53LSL-R270H/ER, KrasLSL-G12D/+;p53LSL-R172H/ER,
KrasLSL-G12D/+;p53Fx/ER, KrasLSL-G12D/+;p53LSL-R270H/Fx,
KrasLSL-G12D/+;p53LSL-R172H/Fx, and KrasLSL-G12D/+;p53Fx/Fx mice
were generated (Jonkers et al. 2001; Christophorou et al. 2005;
Jackson et al. 2005). Lung tumors were induced by intranasal ad-
ministration of Cre-expressing adenovirus, as described previous-
ly (5 × 106 plaque-forming units per mouse; University of Iowa
Vector Core) (Junttila et al. 2010; Kerr et al. 2016). For p53 resto-
ration studies, mice were treated at 15–17 wk after Cre adminis-
tration by intraperitoneal injection with 1 mg of tamoxifen
(Sigma) per mouse once per day (Junttila et al. 2010) or vehicle
(peanut oil) for 1 or 6 d, as indicated. For combined treatments,
mice were irradiated with 4 Gy, (cesium source) 2 h after a single
tamoxifen/vehicle treatment. Stn (200 mg/kg; EP, S0650000) or
vehicle (1% carboxymethylcellulose in water) were administered
15wk after Cre, once daily for 6 d by oral gavage. Transplant stud-
ieswere carried out as described previously (Kerr et al. 2016) using
one cell line per genotype. Prior to transplantation, lung tumor
cells were transducedwithMSCV-luciferase-hygromycin retrovi-
rus and selected (350 µg/mL hygromycin B). Recipient mice re-
ceived either 1 × 105 cells (metastatic potential cohorts) or 1 ×
106 cells (Stn/Ctrl cohorts) by intravenous injection. All plotted
mice developed lung lesions; additional thoracic tumors were ob-
served in somemice. Animals were imaged weekly using an IVIS
Spectrum Xenogen machine (Caliper Life Sciences) as described
previously (Kerr et al. 2016). Stn or control vehicle treatment of
transplantedmodelswas carried out once daily starting 2wk after
transplantation and until endpoint. In all in vivo treatment
groups, lungs were collected 24 h after the last treatment, and a
minimum of three mice per cohort was used (exact values are
indicated).
Immunohistochemistry, immunofluorescence, and tumor grading
Histological analysis was carried out on formalin-fixed, paraffin-
embedded (5-µm) lung tissue sections. Tumor grading was per-
formed on hematoxylin and eosin (H&E)-stained sections accord-
ing to Nikitin et al. (2004) and Junttila et al. (2010) (low grade:
adenomas and grade 1 and 2 adenocarcinoma; high grade: grade
3 and 4 adenocarcinoma). Tumor burden was measured from
H&E sections containing a minimum of four lung lobes per
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section (one section per animal analyzed). The total area of the
section covered by tumors was measured and then calculated as
a percentage of the total lung area on the section using ImageJ
software. The following primary antibodies were used: Ki67:
immunofluorescence, RM-9106 (1:120; Thermo Scientific), im-
munohistochemistry, IHC-00375 (1:200; Bethyl Laboratories);
cleaved caspase-3: 9664S (1:200; Cell Signaling); and p19ARF:
MAB2417 (1:500; Novus). The following corresponding second-
ary antibodies were used: A11008 (1:200) and A21471 (1:200),
both fromThermo Scientific. TUNEL positivity was assessed us-
ing ApopTag kit (Millipore), and tumors were considered positive
if five or more positive nuclei were found per field of view. The
minimum cohort sizes used are indicated.
Generation of lung tumor cell lines
Lung tumor cell lines were generated from independent tumors,
and a minimum of two mice were used per genotype. Tumors
were collected in Hank’s balanced salt solution (HBSS), mashed,
and digested with 4 mg/mL collagenase/dispase (Roche) for 2.5
h at 37°C. Cells were treated with HBSS containing 10% FCS
and DNase I (Invitrogen), filtered (70 µm), and plated in
DMEM/F-12 medium (Life Technologies) with 10% FCS and 4
mML-Glutamine. After 1.5 h, themedium (still containing float-
ing cells) was replated, and tumor cell-enriched (medium: slower
adherence) and TAF-enriched (fast adherence) cultures were
maintained separately. Epithelial and fibroblast content was as-
sessed by EpCAM (Biolegend, 118213) and Pdgfra (eBio-
science,17-1401-81) FACS analysis using a LSRII (BD) flow
cytometer and FlowJo software (TreeStar). All tumor cell lines
used were <8% Pdgfra+. All cell lines used were propagated in
DMEM/F12 medium, tested negative for mycoplasma, and were
typically used between passages 10 and 20 after isolation.
3D cell cultures
To generate 3D cultures, cells were seeded in a 3:2 Matrigel
(Corning, 354234):DMEM/F12mix and allowed to set at 37°C be-
fore additional medium was added. For cell harvesting, Matrigel
was dissociated by incubation with Corning cell recovery solu-
tion (354253) for 45 min at 4°C, and cell pellets were collected
(RNA/protein analysis) or cells were trypsinized (cell counts/
FACS analysis). To assess colony formation, 5000 cells were seed-
ed in Matrigel as above. After 72 h, three to five images were tak-
en for each well at 20× magnification, and colony size was
measured using Image J software. For immunofluorescence, 3D
cultures were fixed in 2% PFA for 1 h followed by 1% glutalde-
hyde for 1 h and then were blocked in 0.15% PBS and 3% Tri-
ton-X serum for 30 min. Antibodies were used at the indicated
concentrations with overnight incubations. For Srebf2 knock-
down, cells were transiently transfected with 10 µg of GFP+
shRNA plasmids (TG510683A-D) or control nontargeting se-
quence (TR30013) fromOrigene. Forty-eight hours after transfec-
tion, cells were sorted for GFP positivity, and 50,000 GFP+ cells
were seeded in Matrigel/DMEM-F12 medium. Colony size was
measured 72 h after seeding as above, and cells were collected
for RNA extraction.
In vitro assays and treatments (2D and 3D cultures)
For growth curve generation, 2D cultures were treated in tripli-
cate with 100 nM 4OHT (Sigma, H7904) or Ctrl (ethanol), and
cell viability was analyzed by Trypan blue exclusion at the indi-
cated time points after treatment start. Where indicated, cells
were administered 10 µM Nutlin3 (VWR)/vehicle (DMSO) or ir-
radiated once with 4 Gy (Xstrahl X-ray irradiator). Combination
treatments were carried out as follows: For irradiation, 4OHT/ve-
hicle was provided 2 h before irradiation, and cell viability was
assessed 48 h after irradiation; for Nutlin3, 4OHT/vehicle and
Nutlin3/vehicle were administered simultaneously, and the me-
dium and drugs were refreshed daily. Cell viability was assessed
24, 48, and 72 h after the beginning of the treatment. Senescence
was assessed 72 h after 4OHT/Ctrl treatment (2D cultures) using
a β-galactosidase staining kit (Cell Signaling, 9860). p53 wild-
type lung cancer cells (A549 and H460) treated with 2 µM palbo-
ciclib (PD-0332991) for 72 h were used as a positive control. Im-
ages were obtained from five random fields of view for each cell
line in triplicate. For BrdU/PI FACS analysis, 2D and 3D cultures
were treated with 100 nM 4OHT/Ctrl for 72 h and processed as
described previously (Kerr et al. 2016). Cell death following 72
h of 4OHT/Ctrl treatment was measured in both 2D and 3D cul-
tures by the ethidium homodimer/calcein AM kit (Molecular
Probes,MP03224). Stnwas activated prior to use as described pre-
viously (Freed-Pastor et al. 2012). Stn (1 µM; Sigma), 10 µM fatos-
tatin (Sigma) in DMSO, 0.3 mMMVA (Sigma) in DMSO, and the
corresponding vehicles were refreshed daily, and viability was as-
sessed by Trypan blue exclusion (72 h). For scratch assays, cells
were cultured for 48 h before each well was scratched twice.
Scratch closure was monitored by Leica live-cell microscopy
with images acquired hourly for 24 h. Velocity was calculated
from three measurements per scratch per cell line, and the aver-
age value was plotted. Invasive growth assays were performed as
reported (Zhou et al. 2014) without addition of EGF to the medi-
um. Intracellular cholesterol levels (2D cultures) were measured
using the Amplex Red cholesterol kit (Molecular Probes,
A12216), and values were normalized to total protein content.
A minimum of two independent cell lines per genotype was
used in all assays (typically three or four, as indicated), except
for fatostatin and shRNA experiments (one cell line per geno-
type). Experimental triplicates were used for all assays.
Microarray analysis, TaqMan validation, and TCGA analysis
Microarray analysis was performed on four independent murine
lung tumor cell lines per genotype cultured in 3DMatrigel. Cells
were cultured for 48 h and then treated with either ethanol (vehi-
cle) or 100 nM 4OHT for 2 or 8 h. Cells were harvested following
dissociation of Matrigel, and RNA was extracted (RNeasy, Qia-
gen). Microarray analysis was carried out using Illumina
MouseWG-6 version 2.0 Expression BeadChip (Department of Pa-
thology, Cambridge University). Arrays were scanned using stan-
dard Illumina protocols, and data were analyzed using R (http:
//www.R-project.org) and Bioconductor (Gentleman et al. 2004).
Spatial artifacts were removed using BASH (Cairns et al. 2008)
and HULK algorithms from the Beadarray package (Dunning
et al. 2007). Datawere log2-transformed and quantile-normalized.
Differentially expressed genes were defined as an average fold
change between groups >1.4 and SD < 0.5 within each cohort to
account for intragenotype variation. Ingenuity Pathway Analysis
(IPA) software (http://www.ingenuity.com) was used for pathway
analysis of differentially expressed genes, and statistical signifi-
cance (P < 0.05) of canonical pathwayswas determined by Fisher’s
exact test. Heat maps were generated using Multiple Experiment
Viewer (MeV). Gene expression changes were validated by quan-
titative PCR using Life Technologies probes. Samples were run in
triplicate, and the datawere normalized to 18S orGAPDHexpres-
sion. p53 “canonical” targets were defined based on functional/
expression studies (gene set enrichment analysis) (Okamoto and
Beach 1994; Lehar et al. 1996; Utrera et al. 1998; Bieging et al.
2014) or ChIP data (http://chip-atlas.org); Fischer 2017). Lung
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adenocarcinoma patient TCGA (The Cancer Genome Atlas Re-
search Network 2014) data were downloaded from cBioportal,
and cases with TP53mutations were divided into conformation-
al, contact, nonmissense, or unclassified based on the TP53mu-
tation. Samples with mutations classified as conformational or
contact by Cho et al. (1994), Joerger et al. (2006), and Joerger
and Fersht (2007) were analyzed for expression of MVA pathway
genes (RNA-seq V2 RSEM). Significance was calculated based
on the Significance Analysis for Microarrays (SAM) platform
(Tusher et al. 2001) within MeV.
Western blotting
Cells lysates were loaded onto 4%–12% Bis-Tris gels, separated
by electrophoresis, and transferred onto a methanol-activated
PVDF (Immobilon) membrane. Primary antibodies against p53
(1:1000; Vector Laboratories, CM5, VP-P956) and Actb
(1:10,000; Sigma, A5441) and their corresponding secondary anti-
bodies (HRP-linked-anti-rabbit [1:2000; Cell Signaling, 7074S] or
anti-mouse [1:3000; Invitrogen, 626520]) were used.
Genotyping and TaqMan probes
Mice and lung cell lines were genotyped as described previously
for KrasG12D (https://jacks-lab.mit.edu/protocols) and p53Fx
(Jonkers et al. 2001). The p53ER PCR primers used were (1) 5′-
CCTCCAGCCTAGAGCCTTCCAAGC-3′, (2) 5′-GGTGAGAT
TTCATTGTAGGTGCC-3′, and (3) 5′-GCACACAAACTCTTC
ACCCTGC-3′. The wild-type band used was 430 base pairs (bp),
and the KI band usedwas 700 bp.Mutant p53 sequencingwas car-
ried out using the following primers: 172: ([1] AGGTGTGTTG
GCCATCTCTG and [2] CTCAGGAGGGTGAGGCAAAC) and
270 ([1] TTTCTGTTCCACGAGTCCCG and [2] AAAAGAC
CTGGCAACCTGCT). The following probes were used for Taq-
Man analysis: Cdkn1a (Mm00432448_m1), Mdm2 (Mm01233
136_m1), Bbc3 (Mm00519268_m1), Mvd (Mm00507014_m1),
Pmvk (Mm01212763_m1), Sqle (Mm00436772_m1), Srebf2
(Mm01306292_m1), Pilra (Mm04211819_m1), Nr2f2 (Mm0077
2789_m1), Slc2a9 (Mm00455122_m1), Phlda3 (Mm0044
9846_m1), Sesn2 (Mm00460679_m1), Bax (Mm00432051_m1),
Gapdh (Mm99999915_g1), and Euk 18S rRNA (4352930E), all
from Applied Biosystems.
Statistical analyses
Statistical analyses were performed using Prism 5.0 software
(Graphpad), with P < 0.05 considered statistically significant. P-
values for unpaired comparisons between two groups with com-
parable variance were calculated by two-tailed Student’s t-test.
One-way ANOVA (between genotypes) was used for analysis be-
tween three groupswith comparable variance followed by Bonfer-
roni post-test for individual comparisons. Kaplan-Meier
comparisonwas used for analysis of survival cohorts, and Fisher’s
exact test was used to analyze tumor grade data.
Accession number
Microarray data were deposited in Gene Expression Omnibus as
GSE94758.
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